pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and Expansion

pharmaand GmbH and GHN Pharma Nordic AB Announce Collaboration Extension and

Vienna, Austria, and Mölndal, Västra Götaland, Sweden, February 1, 2024 –pharmaand
GmbH (pharma&) and GHN Pharma Nordic AB are pleased to announce the renewal
and expansion of their partnership. This marks a significant milestone in a collaboration
that began in 2021, further cementing the relationship and shared vision between the
two companies. In 2021, GHN Pharma Nordic and pharma& embarked on a
transformative journey with a 5-year contract that included Pegasys® (peginterferon
The success of this partnership has paved the way for the recent agreement signed on
December 22, 2023, extending the collaboration for an additional five years starting
January 1, 2024. This new agreement introduces two central medicines to the
partnership: Farydak® (panobinostat) in hematology and Rubraca® (rucaparib) in
oncology. These additions are poised to significantly bolster GHN Pharma Nordic’s
presence in these strategically important areas, demonstrating the potential benefit to
eligible patients. GHN Pharma Nordic has established a strong presence in the Nordic
pharmaceutical market. The Company has successfully launched a diverse range of
medicines through rapid growth and an innovative approach.

“Our extended partnership with pharma& is not just a business agreement; it’s a fusion
of shared goals and visions,” said Tina Madsen Sandström, CEO of GHN Pharma Nordic.
“The addition of Farydak and Rubraca to our portfolio is a significant step in our mission
to provide comprehensive healthcare solutions. We are excited about this new chapter
and the opportunities it brings.”

“The strengthened collaboration with GHN Pharma Nordic reflects the joint
commitment to provide access to essential healthcare solutions,” said Elmar Zagler,
Founder and Managing Director of pharma&.
“We are proud to continue our journey
with a partner who shares our dedication to making a potential difference in the lives of
eligible patients.”
GNH Pharma Nordic looks forward to providing availability updates for Rubraca and
Farydak in the future.

About pharma&
pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe
new life into proven medicines through an agile and fully integrated business model,
guaranteeing the enduring availability, dependability, and quality of essential drugs
worldwide that patients and healthcare providers rely on. Over the past five years,
pharma& has acquired and integrated 12 medicines, expanding its portfolio across a
wide range of therapy areas, with an increasing focus on hematology and oncology
treatments. The Company’s unique synthesis of subsidiaries, joint ventures, and partners
enables pharma& to provide its portfolio of medicines to eligible patients worldwide by
spanning the continuum of development, product and API manufacturing, partner
distribution, healthcare provider engagement, distribution and services to patients.

About GHN Pharma Nordic AB
Since its establishment in late 2021, GHN Pharma Nordic AB has launched prescription
pharmaceuticals in urology, psychiatry, and hematology, medical devices in
dermatology and hematology, and a full range of products in rare metabolic diseases.
With operations across all Nordic countries, GHN Pharma Nordic’s expansion for 2024
includes plans to introduce new pharmaceuticals in dermatology, allergology, and
To the extent that statements contained in this press release are not descriptions of
historical facts regarding pharma&, they are forward-looking statements reflecting
management’s current beliefs and expectations. Examples of forward-looking
statements contained in this press release include, among others, statements regarding
our future financial and operating performance and business plans or prospects. Such
forward-looking statements involve substantial risks and uncertainties that could cause
pharma&’s actual results, performance, or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in pharmaceutical
manufacturing. pharma& undertakes no obligation to update or revise any forward-
looking statements.

GHN Pharma Nordic Contact:
pharma& Media Contact:

Mats Erasmie

Mats Erasmie

Chairman of the board Simplex Motion AB. Consultant in Leadership and Business Development, Erasmie&Erasmie AB.

Key Competence

Sales, Leadership as a part of a strategic changes.

  • MBA, International marketing, University of Stockholm.
  • Certified in Authentic Leadership,Transaction Analysis, Situational Leadership (SL II, Blanchard)
  • Certifed in Insight Discovery, Certifed in DISC
  • Consultant in Leadership and Business Development.
  • Erasmie&Erasmie AB.
  • Chairman of the board Simplex Motion AB.
  • Consultant at Booster Group AB, business development and negotiations.
  • Teacher at IHM, Market Analysis, Practical Marketing and Negotiations.
  • CEO, Chairman of the board and partner; Sällma AB.
  • Vice President Marketing & Sales, Consultant in Leadership and Business.
  • Development at Cordovan Performance Sweden AB.
  • CEO at Lucky Punk AB.

Books and training packages, marketing and sales, twelve in total since 1999

  • ”MED KUNDEN I FOKUS”, Liber Ekonomi 2000
  • ”KUNDRELATIONEN”, Liber Ekonomi 2001
  • ”FÖRSÄLJNING OCH SERVICE”, Liber Ekonomi 2003
  • ”PERSONLIG FÖRSÄLJNING 1”, Liber Ekonomi 2012
  • ”PERSONLIG FÖRSÄLJNING 2”, Liber Ekonomi 2014
  • ”Dödskaravanen”, Historical novel, 2018
  • ”Silverfloden”, Historical novel, 2019
  • Various articles in the magazines Ledarskap, Affärsvärlden and Dagens Industri.

What Now?

You have defined your interest area and the questions related to this.

Now fill in the form and send it to us. The defined contact person from GHN Pharma Nordic will review your interest and contact you within 48 hours.


Get a Contact Person

Pontus Bergman

Valdet Hetemi

Head of Operation & Logistics

Key Competence

Over 17 years of experience within the Pharmaceutical industry; Rx, Medical Devices, Metabolic Diseases, OTC, Logistics and Supply Chain, Business Strategy, Finance, Sales and Marketing, Start-Ups.

  • Education: Master of Business Administration and Bachelor of Social Sciences from the University of Lund and University of Cologne.
  • Head of Operations at POA Pharma Scandinavia AB, Country Manager Sweden at Vitaflo Scandinavia AB/ Navamedic AB, Finance Manager at Vitaflo Scandinavia AB/Navamedic AB.

Ingvar Bosaeus

Martin Svahn

RP& Pharmacist

Key Competence

Martin Svahn is a licensed pharmacist and pharmacy manager.


Licensed Pharmacist at the Universitet of Uppsala, Magisterthesis at the Departement of Anaesthesiology,,University of Uppsala. Master's Program in Clinical Pharmacy University of Uppsakla.

  • Start-up of a new privately owned pharmacy. . Worked in 2013 at K3 as GSST, Since 2014 pharmacy manager at three pharmacies with responsibility for 13-20 employees and an annual turnover of 80 million. "Cluster manager" for Kronan's pharmacy Halland.
Mats Erasmie

Andreas Larsson

Finance Manager

Key Competence

Experience within the Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases and OTC regarding Accounting and Finance Strategy, Financial reporting, Business Development and Logistical support

  • Master of Aeronautical Science at the University of Embry-Riddle Aeronautical University and a degree at the KY academy of finance and accounting at Studium in Gothenburg.
  • Accounting manager at POA Pharma Scandinavia AB, POA Pharma North America and Adrian & Partners AB.

Pontus Bergman

Pontus Bergman

PB Lawyer, founder of Bergman & Eek Advokat AB.

Key Competence

Principal felds of practice are strategically planning for privately owned companies regarding all legal and economical matters. Special focus on developing and establishing new companies or activities abroad, including international tax law for companies and employees.

  • Education: Master of Law from University in Lund
  • Partner at Setterwalls Law Firm
  • Member of the board of POA Pharma AB and in several Swedish privately-own companies.

Tina Madsen Sandström

Tina Madsen Sandström


Key Competence

Over 35 years experience within the international Pharmaceutical industry Rx, Medical Devises, OTC and   Rare Metabolic Diseases. Administration, Leadership, , Licenses & Acquisitions, Start-ups Development, Development, Management, Leadership.



Merkonom, Educated at Hillerød Business School

  • Managing Director for Pharma-Vinci A/S, Member of the branch organisation BFID
  • CEO Vitafo Scandinavia AB
  • CEO POA Pharma Scandinavia AB
  • Director of the board Vitafo Scandinavia AB
  • Director of the board POA Consulting AB
  • Director of the board POA Pharma Scandinavia AB
Roland Sandström

Roland Sandström


Key Competence

45 years experience within the international Pharmaceutical industry Rx, Medical Devices, Metabolic Diseases, OTC. Commercial Strategy, Business Development, License & Acquisitions, Start-ups Development,Management, Organisation Theory.


Master of Political Science at the University of Lund

  • Managing Director Meda Sweden
  • Board member of LSAB and LIF
  • COB Vitafo Scandinavia AB
  • Director of the board Navamedic
  • COB POA Consulting Scandinavia AB
  • COB POA Pharmas Scandinavia AB
  • COB POA Pharma North America
  • Kunden som Kompis (Customer as a Pal)
  • Articles around Project work, organisation theory and marketing
  • Lectures and abstract publications at IPMA in Paris and Ljubljana